GLP-1 medicines, type 2 diabetes and kidney disease

Overview

Many people starting GLP-1 therapy also take diabetes medicines. Adding a GLP-1 agonist usually lowers glucose, so other drugs often need reducing to avoid hypoglycaemia. This is managed in accordance with ABCD (Association of British Clinical Diabetologists) and UKKA joint clinical standards.

Why it's done and who it helps

• Sulfonylureas and insulin frequently need dose reduction at the start to avoid severe hypos.
• Metformin dosing depends on eGFR and is reviewed at each step.
• SGLT2 inhibitors are often continued for kidney protection, following KDIGO 2024 recommendations.
• Home glucose monitoring is advised during escalation if you use insulin.

Hypoglycaemia risk

GLP-1 medicines rarely cause hypoglycaemia alone, but combined with insulin or a sulfonylurea they can. We plan reductions before, not after, the first injection, adhering to NICE NG28 and ABCD guidance on safe medication adjustments.

Kidney-protective combinations

NICE NG203 supports SGLT2 inhibitor use in many people with CKD and albuminuria; GLP-1 therapy is generally complementary rather than an alternative, providing dual protection for heart and kidney.

HbA1c targets

Targets are individualised in CKD, and a rapidly falling HbA1c on top of large weight loss may require insulin dose review every few weeks to prevent complications.

Preparing for your appointment

Will I be able to stop insulin?

Some people reduce substantially; stopping is a decision for your diabetes team.

References

• ABCD-UKKA Joint Guidelines for Diabetes and CKD
• KDIGO 2024 Clinical Practice Guideline
• NICE NG28: Type 2 diabetes in adults: choosing medicines
• Association of British Clinical Diabetologists (ABCD) Position Statements

This article is general patient information reviewed by a consultant nephrologist. It is not individual medical advice; treatment decisions are made at a face-to-face consultation.